Raymond James & Associates’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Raymond James & Associates’s Portfolio ANAC Stock Details ANAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-7,801	Closed	-$417K	–	3193
2016 Q1	$417K	Buy	+7,801	New	+$576K	﹤0.01%	2142
2015 Q4	–	Sell	-13,711	Closed	-$1.61M	–	2474
2015 Q3	$1.61M	Buy	13,711 +3,503	+34%	+$458K	0.01%	1333
2015 Q2	$790K	Buy	10,208 +119	+1%	+$7.8K	﹤0.01%	1844
2015 Q1	$584K	Sell	10,089 -214	-2%	-$9.09K	﹤0.01%	1972
2014 Q4	$332K	Buy	+10,303	New	+$309K	﹤0.01%	2104

Other funds holding ANAC

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Raymond James & Associates's ANAC Position: Q2 2016 in Review

Raymond James & Associates sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 7,801 shares — an estimated $417K sold.

Raymond James & Associates first reported a position in ANAC in Q4 2014 and held it in 5 quarters. The position peaked at $1.61M in Q3 2015. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

Raymond James & Associates reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
Raymond James & Associates sold 7,801 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $417K.
Raymond James & Associates first reported a position in ANACOR PHARMACEUTICALS INC COM in Q4 2014 and held it in 5 quarters.
Raymond James & Associates's ANACOR PHARMACEUTICALS INC COM position peaked at $1.61M in Q3 2015.
2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on Raymond James & Associates's 13F filing for Q2 2016, filed 11 Aug 2016.